stent051408
On the homepage
Vikings
Out There
Artcetera
Television
Study calls Xience stent superior
Another study released Tuesday in Europe also found evidence that drug-coated stents are better than plain.
Print this story
E-mail this story
Save to del.icio.us
Share on Facebook
Share on Digg
Minnesota business by the numbers
See Minnesota's top earning companies, CEOs and non-profits
More from Business
Abbott Laboratories' drug-coated Xience stent prevented heart attacks, kept arteries open and avoided the need for repeat surgeries almost twice as well as Boston Scientific's rival device, according to a study.
The largest-ever trial on Abbott's experimental stent, released Tuesday at the EuroPCR scientific conference in Barcelona, Spain, found 45 percent fewer deaths, heart attacks and follow-up procedures after two years among 1,002 patients who received Xience, compared to those who got Boston Scientific's Taxus, the world's best-selling stent.
The study is key to Abbott's U.S. application to sell Xience and to expand its share of the $5 billion global market for drug-coated stents, the mesh tubes that prop open arteries after they're cleared of clogs, said Kelly Morrison, a company spokeswoman. The results were good enough that an Abbott executive said the company would charge a "premium" above competitors' stent prices.
Shares of the Abbott Park, Ill.-based company rose $1.62, or 3.1 percent, to close $54.40.
Shares of Natick, Mass.-based Boston Scientific, which has major operations in Arden Hills and Maple Grove, fell 40 cents, or 3 percent, to close at $13.01 Tuesday. The company has gained 12 percent this year.
In other news from the conference, Fridley-based Medtronic's drug-coated Endeavor stent performed better than a bare-metal version in a study that further bolsters the safety record of the newest generation of heart devices.
The study of 1,197 people found 14 percent of patients implanted with Endeavor suffered heart attacks, died of heart-related ailments or needed repeat procedures after four years, according to data presented Tuesday. That compared with 23 percent among those who used the company's uncoated stent, named Driver.
The study adds to research showing the latest drug-coated stents more effective than their bare-metal predecessors and challenging 2006 studies suggesting the newer stents might cause more clotting. Endeavor eventually will compete with Abbott Laboratories' Xience stent, Johnson & Johnson's Cypher and Boston Scientific's Taxus for the $5 billion world stent market.
Medtronic fell 73 cents, or 1.5 percent, to close at $47.42.
BLOOMBERG NEWS
Recent Business stories
Griffon subsidiary receives nearly $7 million for Navy communications contract - May 13, 2008
Griffon subsidiary receives nearly $7 million for Navy communications contract - A subsidiary of Griffon Corp., a communications and electronic information business, said Monday it has received a $6.9 million contract to manufacture communications support systems for U.S. Navy helicopters. More
Blog: Patent Pending
Lights out at U energy conference. Irony police notified.
Just as Lawrence Kazmerski, a top official at the National Renewable Energy Laboratory, was about to give the keynote address at the University of Minnesota's annual E3 conference at the RiverCentre in St. Paul, the lights went out, bathing the audience in darkness and a deep sense of irony.
Comment on this story | Be the first to comment | Hide reader comments